Abcam, ab261910, Anti-AGXT antibody [EPR22885-58]

Size: 100µL / 1mL
Rabbit Recombinant Monoclonal AGXT antibody. Suitable for WB, IHC-Fr, Flow Cyt (Intra), IHC-P and reacts with Mouse, Rat, Human samples. Cited in 3 publications.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR22885-58,
Isotype:IgG,
Carrier free:No,
Reacts with:Mouse, Rat, Human,
Applications:WB, IHC-P, IHC-Fr, Flow Cyt (Intra)See reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Specificity:This antibody is not recommended for rat IHC-fr.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The biological target AGXT also known as alanine-glyoxylate aminotransferase plays an important role in human metabolism. It is a liver-specific enzyme with an approximate molecular weight of 43 kDa. AGXT is expressed primarily in liver peroxisomes where it catalyzes the transamination reaction that converts glyoxylate to glycine. This enzymatic activity is important for detoxifying glyoxylate which otherwise could accumulate and result in harmful effects. The expression level and activity of AGXT can be influenced by various metabolic conditions.
Biological function summary
The conversion of glyoxylate to glycine mediated by AGXT helps in maintaining cellular homeostasis. AGXT is not part of large protein complexes but it directly influences the pathways leading to amino acid metabolism. By converting glyoxylate into glycine this enzyme plays a part in managing the precursors necessary for the biosynthesis of other important biomolecules including serine and pyruvate. As glyoxylate is an important intermediary its conversion is essential for metabolic flux.
Pathways
AGXT has a significant role in the glyoxylate metabolic pathway and the glycine serine and threonine metabolism pathway. In these pathways it works closely with other enzymes like glycine decarboxylase and serine hydroxymethyltransferase. The proper functioning of these pathways ensures efficient energy utilization and detoxification in the human body. Any disruption can affect the balance of amino acid concentrations leading to metabolic disturbances.
AGXT is most prominently linked to primary hyperoxaluria type 1 (PH1) which is a rare genetic condition. In PH1 mutations in the AGXT gene lead to its dysfunctional enzyme causing the accumulation of oxalate and subsequent kidney stone formation and renal failure. The disease connection places AGXT in relation to key proteins involved in oxalate metabolism and renal function such as glycolate oxidase. Understanding AGXT's role in these disorders opens pathways for therapeutic interventions and advanced research into metabolic regulation.